Table 3 Characteristics of AML studied cases in comparison to lncRNA TUG1 expression groups

Age (years)

39 ± 14

49 ± 14

0.053

Sex

Males

7 (77.8)

42 (60)

0.301

Females

2 (22.2)

28 (40)

Initial TLC (× 10³)

25 (0.7–316)

20 (0.3–403)

0.982

Initial HGB

7.5 ± 1.1

7.8 ± 1.9

0.620

Initial PLT (× 10³)

70 (6–208)

45 (4–166)

0.537

Initial PB blasts (%)

25 (4–92)

60 (0–100)

0.222

Initial BMA blast (%)

64 (21–88)

76 (20–98)

0.034

Initial cellularity

Hypocellularity

0 (0)

2 (2.9)

1.0

Hypercellularity

8 (88.9)

58 (82.9)

Normocellularity

1 (11.1)

10 (14.3)

Hepatomegaly

0 (0)

16 (22.9)

0.108

Splenomegaly

0 (0)

15 (21.4)

0.123

Lymphadenopathy

2 (22.2)

24 (34.3)

0.468

Fever

4 (44.4)

32 (45.7)

1.0

Positive CD34

7 (77.8)

35 (50)

0.162

Positive HLA-DR

5 (55.6)

40 (57.1)

0.928

Positive MPO (cyto)

7 (77.8)

60 (85.7)

0.532

Positive CD33

8 (88.9)

62 (88.6)

0.977

Positive CD13

5 (55.6)

62 (88.6)

0.009

Positive CD117

7 (77.8)

52 (74.3)

0.821

Positive CD14

2 (22.2)

13 (18.6)

0.793

Positive CD4

1 (11.1)

5 (7.1)

0.672

Positive CD11c

3 (33.3)

16 (22.9)

0.489

Positive CD64

2 (22.2)

22 (31.4)

0.572

Positive CD61

0 (0)

2 (2.9)

1.0

Positive CD7

1 (11.1)

4 (5.7)

0.463

Abnormal cytogenetics

6 (75)

30 (50)

0.266

Negative FLT-ITD

8 (88.9)

52 (74.3)

0.335

Positive FLT-ITD

1 (11.1)

18 (25.7)

Wild NPM

8 (88.9)

66 (94.3)

0.463

Mutant NPM

1 (11.1)

4 (5.7)

t(8:21)

1 (11.1)

4 (5.7)

0.463

PML/RARA

0 (0)

7 (10)

1

t(16:16)/inv16

1 (11.1)

1 (1.4)

0.216

t(9:22)

1 (11.1)

1 (1.4)

0.216

FAB

M0

0 (0)

2 (2.9)

0.529

M1

0 (0)

13 (18.6)

M2

4 (44.4)

26 (37.1)

M3

1 (11.1)

7 (10)

M4

4 (44.4)

13 (18.6)

M5

0 (0)

7 (10)

M6

0 (0)

0 (0)

M7

0 (0)

2 (2.9)

Genetic risk (ELN 2017)

Favorable

3 (33.3)

15 (21.4)

0.282

Intermediate

2 (22.2)

34 (48.6)

Poor

4 (44.4)

21 (30)

Treatment response

BMA blast on day 14

3 (1–70)

2 (0–90)

0.415

BMA blast on day 28

4 (0–30)

2 (0–88)

0.1